arrow_back Back to App

Matt's Act: Limiting Insulin Prices for Diabetics

This act aims to reduce insulin costs for individuals with diabetes, whether insured or uninsured. Insulin manufacturers will be required to publish average prices, and insurers and pharmacies must offer insulin at reduced rates, making the medication more accessible and easing financial burdens.
Key points
Insulin manufacturers must publish quarterly average net prices of their products online.
Insured individuals (group or individual plans) will pay no more than 10% of the average net price plus distribution costs, or $20, whichever is less. For high-deductible plans, insulin will be free.
Uninsured individuals can purchase insulin at pharmacies for the average net price plus distribution costs, which cannot exceed 10% of the average net price.
The act waives deductibles for insulin for insured individuals.
Distribution and dispensing charges for insulin cannot exceed 10% of the average net price of the drug.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_4813
Sponsor: Rep. Fortenberry, Jeff [R-NE-1]
Process start date: 2021-07-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Matt’s Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4813.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-07-29.

What are the main provisions?

Key points include:

  • Insulin manufacturers must publish quarterly average net prices of their products online.
  • Insured individuals (group or individual plans) will pay no more than 10% of the average net price plus distribution costs, or $20, whichever is less. For high-deductible plans, insulin will be free.
  • Uninsured individuals can purchase insulin at pharmacies for the average net price plus distribution costs, which cannot exceed 10% of the average net price.
  • The act waives deductibles for insulin for insured individuals.
  • Distribution and dispensing charges for insulin cannot exceed 10% of the average net price of the drug.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Fortenberry, Jeff [R-NE-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health